Rice Hall James & Associates LLC Buys Shares of 189,907 LeMaitre Vascular, Inc. $LMAT

Rice Hall James & Associates LLC bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, HoldingsChannel reports. The fund bought 189,907 shares of the medical instruments supplier’s stock, valued at approximately $18,223,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Kennedy Capital Management LLC increased its stake in LeMaitre Vascular by 14.8% in the fourth quarter. Kennedy Capital Management LLC now owns 247,907 shares of the medical instruments supplier’s stock valued at $20,105,000 after acquiring an additional 32,040 shares during the last quarter. Wakefield Asset Management LLLP bought a new stake in LeMaitre Vascular during the fourth quarter worth $1,130,000. Vanguard Group Inc. lifted its stake in LeMaitre Vascular by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after purchasing an additional 21,946 shares during the last quarter. Riverbridge Partners LLC acquired a new stake in shares of LeMaitre Vascular in the 1st quarter valued at $11,528,000. Finally, M&T Bank Corp boosted its holdings in shares of LeMaitre Vascular by 2,240.5% in the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after purchasing an additional 381,061 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 0.2%

NASDAQ LMAT opened at $82.51 on Tuesday. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. LeMaitre Vascular, Inc. has a twelve month low of $78.65 and a twelve month high of $118.01. The company has a market cap of $1.89 billion, a price-to-earnings ratio of 28.95, a price-to-earnings-growth ratio of 2.38 and a beta of 0.53. The business’s fifty day moving average is $95.25 and its 200 day moving average is $99.75.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The firm had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. During the same quarter in the prior year, the firm earned $0.60 EPS. The company’s revenue was up 9.6% on a year-over-year basis. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular’s payout ratio is 35.09%.

Analysts Set New Price Targets

A number of research firms have recently commented on LMAT. Wells Fargo & Company lowered their price target on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday, August 5th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Citizens Jmp boosted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.